SUBSCRIBERS

Bumper crop of new drugs fails to lift big pharma R&D returns

Projected returns at 12 top drugmakers falls to an 8-year low of only 3.2%: Deloitte

Fri, Dec 15, 2017 - 5:50 AM

London

SO FAR this year, the US Food and Drug Administration, gatekeeper to the world's biggest drugs market, has approved 41 novel drugs compared with 22 for the whole of 2016.

It is shaping up to be a bumper year for drug approvals, with US officials clearing twice as many novel...

To continue reading

for full content

if you are a subscriber

Get our introductory offer at only

$0 .99*/month

Cancel anytime

*$0.99/month for first 3 months

$29.90/month for the next 9 months

Need help?

CALL +65 6388 3838 EMAIL btocs@sph.com.sg

OPERATING HOURS (+8 GMT) MON-FRI: 8:30AM-5:30PM

Register to read this article. Log in if you are already a subscriber. Register to read this article. Log in if you are already a subscriber. Please log in or subscribe to continue reading.